Bernie Sanders slams pharmaceutical company charging $375K for a drug which was free for years
Sanders asked Catalyst Pharmaceuticals explain both the financial and non-financial factors the company considered when it set the list price for Firdapse in December.
United States Senator Bernie Sanders slammed Catalyst Pharmaceuticals on Monday in a letter, asking the firm to justify their decision of charging $375,000 annually for a drug which was available to patients for free for years.
Sanders asked the firm to explain both the financial and non-financial factors the company considered when it set the list price for Firdapse in December, according to reports. Sanders' letter was reportedly dated February 4. Fidapse is reportedly used to treat a rare neuromuscular disorder called the Lambert-Eaton Myasthenic Syndrome (LEMS), and in which the immune system attacks the body's own tissues. The disorder affects nearly one in 100,000 people in the US.